Collegium Pharmaceutical Inc (NASDAQ:COLL) – Equities research analysts at Cantor Fitzgerald lowered their FY2018 EPS estimates for Collegium Pharmaceutical in a report issued on Tuesday, January 8th. Cantor Fitzgerald analyst B. Folkes now forecasts that the specialty pharmaceutical company will post earnings of ($1.87) per share for the year, down from their previous forecast of ($1.83). Cantor Fitzgerald has a “Buy” rating and a $35.00 price objective on the stock.
A number of other analysts have also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating on shares of Collegium Pharmaceutical in a research report on Monday, September 17th. BidaskClub cut Collegium Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 18th. ValuEngine raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Tuesday, November 13th. Finally, Zacks Investment Research raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Collegium Pharmaceutical has an average rating of “Buy” and a consensus price target of $30.43.
Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.14). Collegium Pharmaceutical had a negative net margin of 30.13% and a negative return on equity of 70.06%. The business had revenue of $70.20 million during the quarter, compared to analyst estimates of $74.79 million. During the same period in the previous year, the business earned ($0.45) earnings per share. The business’s quarterly revenue was up 485.0% on a year-over-year basis.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC bought a new position in Collegium Pharmaceutical during the 2nd quarter worth $213,000. Atria Investments LLC increased its stake in Collegium Pharmaceutical by 81.3% during the 3rd quarter. Atria Investments LLC now owns 15,307 shares of the specialty pharmaceutical company’s stock worth $226,000 after acquiring an additional 6,866 shares during the period. Jefferies Group LLC bought a new position in Collegium Pharmaceutical during the 3rd quarter worth $271,000. Capital Fund Management S.A. bought a new position in Collegium Pharmaceutical during the 3rd quarter worth $286,000. Finally, Man Group plc bought a new position in Collegium Pharmaceutical during the 3rd quarter worth $287,000.
In other news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $16.53, for a total transaction of $413,250.00. Following the transaction, the director now owns 361,000 shares in the company, valued at $5,967,330. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last quarter, insiders have sold 75,000 shares of company stock worth $1,282,750. 13.87% of the stock is owned by corporate insiders.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.